HN31 cells (1 105) were injected directly into the dorsal tongue and the size (length and width) of lesions in the tongue was monitored weekly. tested bothin vitroandin vivo. We also showed that DR5 was indicated on the surface of the tested cell lines which correlated with the cellular susceptibility to apoptosis induced by rhTRAIL and anti-DR5 antibody. By contrast, little or no DR4 was recognized on the surface of OSCC3 and HN6 cells rendering cellular resistance to DR4 antibody and a reduced level of sensitivity to rhTRAIL. Notably, the overall TRAIL level of sensitivity correlated well with the levels of endogenous active Ras in the cell lines tested. Expression ML277 of a constitutively active Ras mutant (RasV12) in OSCC3 cells selectively upregulated surface manifestation of DR5, but not DR4, and restored TRAIL level of sensitivity. Our findings could have implications for the use of TRAIL receptor targeted therapies in the treatment of human being OSCC tumors particularly the ones harboring constitutively active Ras mutant. Keywords:oral cancer, TRAIL, death receptors, apoptosis, Ras, oncotarget == Intro == Dental squamous cell carcinoma (OSCC) is the most common oral and pharyngeal malignancy that affects approximately 500,000 fresh instances yearly worldwide [1,2]. Despite the aggressive management including surgery, radiation, and chemotherapy [3], most individuals with advanced OSCC develop local or regional recurrences and distant metastasis that accounts for a poor prognosis that has remained unchanged for decades [4,5]. There is an unmet need for more effective and less harmful molecularly targeted therapies for treating this disease. TNF-related apoptosis inducing ligand (TRAIL) induces apoptosis through its death receptors (DRs) 4 and/ 5 indicated on the surface of target cells. Both receptors are characterized by a cytoplasmic death website that, upon ligand binding, facilitates the assembly of the death-inducing signaling complex (DISC) including procaspase-8 or -10 [6,7]. Within the DISC, procaspase-8 or -10 is definitely self-cleaved and triggered, resulting in subsequent activation of a caspase cascade, cleavage of cellular proteins, and eventually apoptotic cell death. Preclinical data show that recombinant human being TRAIL (rhTRAIL) can induce apoptosis in a broad range of human being tumor cell lines while sparing most normal cell types [8-11]. In tumor xenograft models, rhTRAIL exhibits single-agent antitumor activity and/or assistance with particular standard and targeted treatments [11-14]. These unique properties of TRAIL have advertised multiple clinical tests that are currently ongoing to test rhTRAIL and monoclonal antibodies to DR4 or DR5 for the treatment of numerous malignancies, including melanoma, ovarian, renal, and colorectal cancers [15,16]. However, several issues remain to be resolved such as the recognition of tumor types that are mostly susceptible to TRAIL based therapies, and the ML277 detection of biomarkers predictive of tumor level of sensitivity. Indeed, Rabbit Polyclonal to MMP-7 little is known about the apoptosis-inducing activity of rhTRAIL and its agonistic antibodies in OSCC cells. The energy of TRAIL like a malignancy therapy is limited from the development of drug resistance in malignancy cells. Many factors have been reported to impact TRAIL-induced apoptosis, including decoy receptors DcR1, DcR2 ML277 and OPG that lack a death website but compete with DR4/DR5 for TRAIL binding, the manifestation of inhibitory proteins in transmission transduction pathways such as c-FLICE-inhibitory protein (FLIP) [17] and IAP family proteins [18], and deficiency in caspase-8 [19]. We while others have recently demonstrated the post-translational modifications of DR4 and DR5 receptors, including O-glycosylation [20] and endocytosis [21-23], are also a critical determinant of cellular level of sensitivity to TRAIL centered therapies. Recent evidence suggests that oncogenic Ras may also be involved in the rules of TRAIL receptors, therefore sensitizing malignancy cells to TRAIL-induced apoptosis [24-26]. Ras signaling is definitely often triggered in human being tumors including OSCC [27-29], where it contributes to the tumorigenicity through connection with numerous downstream effector focuses on, such as MEK, PI3K, and Rho GTPases [30,31]. Ras regulates a Raf-MEK-ERK1/2 kinase cascade which has been shown to sensitize colon cancer cells to TRAIL-induced apoptosis by ML277 up-regulating DR4 and DR5 [24,25]. TRAIL resistance is also seen in OSCC cell lines [32-35], and the underlying mechanisms remain to be better recognized. To explore the potential of focusing on death receptors against OSCC, we tested the apoptosis-inducing activity of rhTRAIL and its agonistic antibodies inside a panel of OSCC cell lines..
